Adjuvant treatment in melanoma. María González Cao Servicio Oncología Médica Institut Universitari Dexeus-Quiron. Barcelona Formigal, 24th June 2016
|
|
- Rosanna Stokes
- 6 years ago
- Views:
Transcription
1 Adjuvant treatment in melanoma María González Cao Servicio Oncología Médica Institut Universitari Dexeus-Quiron. Barcelona Formigal, 24th June 2016
2 Charles M. Balch et al. JCO 2009;27: Survival by AJCC stages
3 Breast Cancer Oncotype This material has been prepared by the WW medical team for internal training purposes. It may also be used externally but only after local approval has been obtained.
4 Melanoma-specific survival for sentinel-node tumor burden according to (A) Rotterdam criteria, (B) subcapsular location, and (C) Rotterdam-Dewar Combination criteria Submicrometastases in the subcapsular: NSN positivity rate 2% and MSS 10y of 95% Augustinus P.T. van der Ploeg et al. JCO 2011;29:
5 BRAF IIIB/C 134 patients lymphadenectomy and no adjuvant treatment: 39 BRAF+ G Long 2011
6 NRAS and BRAF Mutational Status and MSS Higher-Risk Primary Melanoma JAMA Oncol. 2015;1(3):
7 Figure 4 PD-L1 and NKG2D on CD8 blood cells and TILs Zitvogel 2016 Journal of Investigative Dermatology , DOI: ( /j.jid )
8 Adjuvant treatments Failled BCG BVZ Cellular vaccines Biochemo? FDA Approved Interferon alpha IIB/C and III 1995 Pegintron III 2001 Ipilimumab-----III 2015 Ongoing Anti PD-1/PD-L1 (KEYNOTE054; CheckMate238) BRAF/MEKi (COMBI-AD; BRIM-8)
9 Interferon Producing cells IFN alpha Plasmocitoi IFN beta d dendrtics Fibroblast Most cells IFN gamma TH1 Inhibitories CK IL10 Activating CK IL12
10 Interferon Acción antiproliferativa Activación de NK Sobreregulación de HLA I y II antígenos Antiangiogénico
11 Ivaskiv. Nature 2015.
12 Ivaskiv. Nature 2015.
13 Ivaskiv. Nature 2015.
14 PRRPs: pattern recognition receptors Figure 2 Three members: RIG-1 (retinoic acid inducible gene 1)(also known as DDX58) i MDA-5 (melanoma differentiation associated gene 5) LGP2: laboratory of genetics and phisiology 2 : negative regulator dsrna also recognized by TLRs (in mbrane or endosomes). Chiappinelli et al. Cell 2015
15 Dear, NEJM, 2016
16 Enhancing Tumor-Cell Visibility to the Immune System with the Use of Viral Mimicry Dear AE. N Engl J Med 2016;374:
17 Persistent type I interferon exposure in chronic infection induces immunosuppression Ivaskiv. Nature 2015.
18 IFN alpha Neoadyuvant 20 pac, RO 55%, p RC 15% Moschos, S. J. et al. J Clin Oncol; 24:
19 Immunohistochemical staining for CD3 (A, B) and CD11c (C, D) in melanoma-infiltrated lymph nodes from a clinical responder before (A, C) and after (B, D) treatment Moschos, S. J. et al. J Clin Oncol; 24:
20 Wang W, Kirwood JM. Clin Cancer Res 2007 Wang. Cancer Imm Immunotherapy 2008
21 IFN regimens Low doses: 3 MU per day for 3 d/w Medium doses: 5 to 10 MU per day sc for 3 to 5 d/w High dose: 20 MU/m2/d iv for 5 d/w followed by 11 months of intermediate-dose sc IFN with 10 MU/m 2 /d for 3 d/w.
22 Low/intermedium doses
23 High doses IFN
24 Efficacy in ECOG Individual Studies: Improvement in RFS but Not OS in the Adjuvant Setting High-Dose IFN- -2b (n=143) Observation (n=137) Median RFS, Years P= Median OS, Years P= Efficacy in ECOG High-Dose IFN- -2b Low-Dose IFN- -2b Observation 5-Year RFS, % Year OS, % Efficacy in ECOG GMK IFN- -2b Relapse at 16 Months 39% 25% P= OS at 16 Months 1.52 in favor of IFN- -2b P= Kirkwood JM, et al. J Clin Oncol. 1996;14: Kirkwood JM, et al. J Clin Oncol. 2000;18: Kirkwood JM, et al. J Clin Oncol. 2001;19:
25 ECOG 1684
26 (A) E1684 at median follow-up of 12.6 years, (B) E1690 at a median follow-up of 6.6 years, (C) E1694 at a median follow-up of 2.1 years, and (D) E2696 at a median follow-up of 2.8 years John M. Kirkwood et al. Clin Cancer Res 2004;10:
27 John M. Kirkwood et al. Clin Cancer Res 2004;10:
28 Survival of pooled analysis of E1684 and E1690 (n = 713) John M. Kirkwood et al. Clin Cancer Res 2004;10:
29 Forest plot of hazard ratios (HRs) (interferon alpha [IFN-α] vs control) for DFS Simone Mocellin et al. JNCI J Natl Cancer Inst 2010;102:
30 Forest plot of hazard ratios (HRs) (interferon alpha [IFN-α] vs control) for OS Simone Mocellin et al. JNCI J Natl Cancer Inst 2010;102:
31 Qué población se beneficia? 1 ganglio ganglios 1690 T4 N0 1694
32 Safety in ECOG 1690 (Incidence of Grade 3 and 4 AEs Occurring in 5% of Patients) 1 Toxicity Type, n (%) High-Dose IFN- -2b (n=212) Low-Dose IFN- -2b (n=214) Observation (n=207) Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Granulocytopenia 85 (40) 9 (4) 12 (6) Liver toxicity 61 (29) 0 8 (4) 1 (0.05) 6 (3) 0 Fatigue 49 (23) 2 (1) 7 (3) Neuroclinical 42 (20) 0 14 (6) 0 2 (1) 0 Myalgia 35 (16) 2 (1) 18 (8) Leukopenia 30 (14) 0 2 (1) Nausea 19 (9) 0 5 (2) 0 2 (1) 0 Neuropsychiatric 18 (8) 2 (1) 5 (2) Neuromotor 12 (6) 1 (0.05) 2 (1) Vomiting 11 (5) 1 (0.05) 3 (1) 0 2 (1) 0 AEs, adverse events. 1. Kirkwood JM, et al. J Clin Oncol. 2000;18:
33 Reducción o retraso dosis E1684 n % E1690 n % E1694 n % Inducción 53/ / / Manteni miento 46/ / /356 37
34 EORTC Pegylated IFN-a-2b, 6mg/kg/w sc for 8 w, then 3mg/kg/w for 5y EORTC 18991:Stage IIII; At 7.6 years median follow-up, 384 recurrences or deaths had occurred with pegylated IFN-a-2b vs 406 in the observation group (P=0.055) 4 There was no significant effect on OS or distant metastasis-free survival DeCOG 3 MIU por 18m vs 60m en N0 y T>1.5mm: ns DFS, JCO 08 Bottomley. J Clin Oncol 09, Eggermont, Lancet 08
35 This material has been prepared by the WW medical team for internal training purposes. It may also be used externally but only after local approval has been obtained. Ipilimumab Clinical Trials in Adjuvant Melanoma Trial NCT Identifier Phase Comparator Stage N Outcome EORTC 18071/CA NCT placebo III 951 ECOG NCT IFN- -2b III-IV 1545 (estimated enrollment) Moffitt pilot study 3 NCT NA IIIc/IV 75 RFS (P=0.0013) RFS, OS (--) OS, RFS (NR) 1. Eggermont AM, et al. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL. 2. Clinicaltrials.gov. Accessed on December 1, Sarnaik AA, et al. Clin Cancer Res. 2011;17:
36 Study EORTC 18071/CA A phase 3 study of ipilimumab versus placebo to prevent recurrence after complete resection of high-risk stage III melanoma (NCT ) R0 Stage III skin melanoma (LN >1 mm, no in-transit mets) No prior treatment (except surgery) N=951 R a Ipi high dose N=475 Induction Phase 10 mg/kg IV Q3W 4 Placebo N=476 Induction Phase 10 mg/kg IV Q3W 4 Maintenance Phase 10 mg/kg IV Q3M 12 Maintenance Phase 10 mg/kg IV Q3M 12 Stratification factors: Stage (IIIA vs IIIB vs IIIC 1-3 positive lymph nodes vs IIIC 4 positive lymph nodes) Regions (North America, European countries, and Australia)
37 Ipilimumab EORTC18071 Ongoing ECOG IFN vs IPI 3 vs 10 Eggermont. Lancet Oncol 2015
38 EORTC 18071/CA : Patient Disposition and Treatment 1 Ipilimumab (n=471) Placebo (n=474) Discontinuation, % a Reasons for discontinuation, % Normal completion a Disease progression AE related to study drug Other reasons b Median doses, per patient Mean doses, per patient Receiving 1 maintenance dose, % Receiving 7 doses (1 year of therapy), % a 1.9% of patients in the ipilimumab group and 3.0% in the placebo group had 16 cycles reported as per protocol without a documented reason for discontinuation. b Less than 1% difference between groups; includes AE unrelated to study drug, both (related and unrelated to study drug), patient request, poor/noncompliance, death, pregnancy, patient no longer eligible, other. 1. Eggermont AM, et al. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL.
39 EORTC 18071/CA Safety: iraes 1 Patients, % Ipilimumab (n=471) Placebo (n=474) All grades Grade 3 Grade 4 All grades Grade 3 Grade 4 Any irae Dermatologic Rash Gastrointestinal Diarrhea Colitis a Endocrine Hypophysitis Hypothyroidism Hepatic LFT increase Neurologic Other a Gastrointestinal perforations: ipilimumab, 6 related (1.3%); placebo, 3 unrelated (0.6%). 1. Eggermont AM, et al. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL.
40 Proportion With Event Proportion With Event Proportion With Event Proportion With Event EORTC 18071/CA : Time to Onset of Grade 2-5 iraes Skin 0.35 Gastrointestinal Ipilimumab 10 mg/kg (n=471) Placebo (n=474) Median time to onset (ipilimumab): 4.3 weeks (range: ) Median time to onset (ipilimumab): 6.3 weeks (range: ) Number of Doses Number of Doses 0.35 Hepatic 0.35 Endocrine Median time to onset (ipilimumab): 8.7 weeks (range: ) Median time to onset (ipilimumab): 10.8 weeks (range: ) Number of Doses Number of Doses 1. Eggermont AM, et al. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL.
41 EORTC 18071/CA : Resolution of Grade 2-4 iraes 1 Ipilimumab (n=471) Placebo (n=474) Skin irae N with event Resolved, n (%) 115 (89.1) 13 (92.9) Median, weeks (95% CI) 5.5 ( ) 2.6 ( ) Gastrointestinal irae N with event Resolved, n (%) 135 (93.8) 17 (94.4) Median, weeks (95% CI) 4.0 ( ) 0.9 ( ) Hepatic irae N with event 77 5 Resolved, n (%) 73 (94.8) 4 (80.0) Median, weeks (95% CI) 5.0 ( ) 12.0 (1.1-NR) Endocrine irae N with event Resolved, n (%) 75 (56.0) 4 (80.0) Median, weeks (95% CI) 31.0 ( ) 12.6 (3.4-NR) NR, not reached. 1. Eggermont AM, et al. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL.
42 EORTC 18071/CA : Deaths 1 Five patients (1.1%) died due to drug-related AEs in the ipilimumab group 3 patients with colitis (2 with gastrointestinal perforations) 1 patient each with myocarditis 1 patient with Guillain-Barré syndrome had multi-organ failure 1. Eggermont AM, et al. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL.
43 Phase 3 Study ECOG Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (NCT ) Arm A: Ipi High Dose n=500 Induction Phase 10 mg/kg IV Q3W 4 Maintenance Phase 10 mg/kg IV Q3M 4 R0 Stage IIIB- IV (M1a/b) (no IIIA) N=1500 R a Arm B: : Ipi High Dose n=500 Induction Phase 20 MU/m 2 IV 5 /wk 4 wk Maintenance Phase 10 MU/m 2 SC TIW Arm C: Ipi Low Dose n=500 Induction Phase 3 mg/kg IV Q3W 4 Maintenance Phase 3 mg/kg IV Q3M 4 1. Clinicaltrials.gov. Accessed on December 1, 2014.
44 Phase 3 Study ECOG (cont d) Coprimary endpoints: RFS and OS Secondary endpoints: Safety and quality of life Current estimated enrollment: 1545 (1-Dec-14) Study Start Date: May 2011 Estimated Primary Completion Date: May Clinicaaltrials.gov. Accessed on December 1, 2014.
45 Randomization 1:1 Design: CA Screening Double-Blind Treatment Follow -Up Stage IIIb/c or stage IV Previously untreated Tumor tissue available for PD-L1 testing Pathology report (Stage III and IV) Arm A ipilimumab 10 mg/kg (IV Q3W for 4 doses and then every 12 weeks starting at WK 24) + nivolumab placebo IV Q2 weeks Arm B nivolumab 3 mg/kg IV Q2 weeks + ipilimumab placebo IV Q3W for 4 doses and then every 12 weeks starting at WK 24 Post treatment follow-up for safety, recurrence events, and overall survival 2 visits: 1 & 2 Survival Follow-up visit Primary Endpoint: Recurrence Free Survival Treat until disease recurrence or unacceptable toxicity with maximum one year Secondary Endpoint: Overall Survival
46 Randomization 1:1 Keynote-054 Screening Double-Blind Treatment Follow -Up Stage III Previously untreated Tumor tissue available for PD-L1 testing Arm A placebo Post treatment follow-up for safety, recurrence events, and overall survival Arm B Pembrolizumab 200mg iv 3w for 12m Treat until disease recurrence or unacceptable toxicity with maximum one year Survival Follow-up visit Primary Endpoint: Recurrence Free Survival in PD-L1 + Secondary Endpoint: Overall Survival
47 Unsupervised hierarchical clustering of 83 primary melanoma Véronique Winnepenninckx et al. JNCI J Natl Cancer Inst 2006;98:
48 Pedram Gerami et al. Clin Cancer Res 2015;21: prognostic 28-gene signature
49 Back up slides
50 Figure 1 Journal of Investigative Dermatology , DOI: ( /j.jid ) Copyright 2016 The Authors Terms and Conditions
51 Figure 2 Journal of Investigative Dermatology , DOI: ( /j.jid ) Copyright 2016 The Authors Terms and Conditions
52 Figure 3 Journal of Investigative Dermatology , DOI: ( /j.jid ) Copyright 2016 The Authors Terms and Conditions
53 Figure 4 Journal of Investigative Dermatology , DOI: ( /j.jid ) Copyright 2016 The Authors Terms and Conditions
54 Figure 5 Journal of Investigative Dermatology , DOI: ( /j.jid ) Copyright 2016 The Authors Terms and Conditions
55
56 mucosal Chemo
57 mucosal Chemo
58
59
60
61
62
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationAdjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationNeoadjuvant approaches to the establishment of adjuvant therapeutic efficacy with IFN, anti-ctla4 and
Neoadjuvant approaches to the establishment of adjuvant therapeutic efficacy with IFN, anti-ctla4 and combinations Ahmad A. Tarhini, MD, PhD Assistant Professor of Medicine, Clinical i l and Translational
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationRevolution in der adjuvanten Therapie des Melanoms? Was bleibt? Was wird sich verändern?
Revolution in der adjuvanten Therapie des Melanoms? Was bleibt? Was wird sich verändern? Dr. Peter Mohr, Elbeklinikum Buxtehude Hautkrebszentrum Oktober 217 Approved treatments for melanoma in the adjuvant
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationSentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma
Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma John A Zitelli MD Adjunct Clinical Associate Professor Dermatology, Otolaryngology, Plastic Surgery University of Pittsburgh
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationManaging immune related toxicity. Karijn Suijkerbuijk May 27 th 2017
Managing immune related toxicity Karijn Suijkerbuijk May 27 th 2017 Disclosures Advisory role: BMS, Merck Travel support: Amgen, Novartis, Roche Whybother? Patients are dying from toxicity Eggermont ipilimumab
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationNCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18
ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationNivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1
For public no AIC or CIC Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1 1st Appraisal Committee meeting Committee
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationThe Challenge of Bringing Forward New Agents for Systemic Therapy of Melanoma
The Challenge of Bringing Forward New Agents for Systemic Therapy of Melanoma John M. Kirkwood, MD Director, Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute Professor & Vice
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationClinical Perspectives Highlights from the Perspectives in Melanoma XII Conference Scheveningen/The Hague, the Netherlands, October 2-4, 2008
ADJUVANT THERAPY Clinical Perspectives Highlights from the Perspectives in Melanoma XII Conference Scheveningen/The Hague, the Netherlands, October 2-4, 2008 Updated analysis and discussion of current
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationToxicity of Systemic Melanoma Therapies. Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney
Toxicity of Systemic Melanoma Therapies Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney Disclosures Advisory Board Novartis, BMS, Sanofi, Pfizer Travel support
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationSurgical Treatment of Melanoma Across the Disease Spectrum:
AOCD Annual Fall Meeting October 28 th, 2017 New Orleans, Louisiana Surgical Treatment of Melanoma Across the Disease Spectrum: Standards of Care and Evolving Paradigms Merrick Ross, M.D. Professor of
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationUnmet Need Mucosal and Uveal Melanoma
Unmet Need Mucosal and Uveal Melanoma Matteo Carlino Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals Melanoma Institute Australia The University of Sydney. Cutaneous Overall Survival
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Ipilimumab (Yervoy ) in the adjuvant therapy for high-risk stage III cutaneous melanoma DSD: Horizon Scanning in Oncology No. 67 ISSN online 2076-5940 Horizon Scanning in
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More information